Augmentation of natural immunity to a proinflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis

Gene Therapy

Volumn 6, Issue 6, 1999, Pages 1128-1138

  Wildbaum, G ^a   Karin, N ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

CNS; DNA vaccination; Experimental autoimmune encephalomyeltis; Natural immunity; Neutralizing antibodies; TNF

Indexed keywords

BETA ACTIN; CYTOKINE; DNA VACCINE; IMMUNOGLOBULIN G; MESSENGER RNA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE RESISTANCE; FEMALE; GENE TARGETING; IMMUNE SYSTEM; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALS; ANTIBODIES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNITY, NATURAL; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

ANIMALIA;

EID: 0033058502     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300915     Document Type: Article

References (97)

1. Alvord ECJ, Kies MW, Suckling AJ (eds). Experimental Allergic Encephalomylitis: A Useful Model for Multiple Sclerosis, 1st edn. Allen R Liss: New York, 1984.
2. MacFarlin D, MacFarland H. Multiple sclerosis. New Engl J Med 1983; 307: 1183-1188.
3. Karin N et al. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J Immunol 1993; 150: 4116-4124.
4. Yednock TA et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
5. Karin N et al. Reversal of experimental autoimmune encephalomyelitis as soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of IFN-γ and TNF-α production. J Exp Med 1994; 180: 2227-2237.
6. Karin N et al. Short peptide based tolerogens without antigenic activity reverse autoimmunity. J Immunol 1998; 160: 5188-5194.
7. Brocke S et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343-346.
8. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 167-176.
9. Issazadeh S et al. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 1995; 61: 205-212.
10. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992; 149: 2496-2505.
11. Villarroya H et al. Expression of TNF alpha in central neurons of Lewis rat spinal cord after EAE induction. J Neurosci Res 1997; 49: 592-599.
12. O'Garra A, Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994; 6: 458-466.
13. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
14. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145: 3796-3806.
15. Lederer JA et al. Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med 1996; 184: 397-406.
16. + T cells to enhance priming for IFN-γ production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sci USA. 1993; 90: 10188-10192.
17. + T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-1098.
18. Fiorentino DF et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
19. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 9: 145-173.
20. Mosmann T, Moor K. The roie of IL-10 in the crossregulation of Th1 and Th2 responses. Immunol Today 1989; 12: A49-A53.
21. Huang H et al. IL-4 and IL-13 production in differentiated T helper type 2 cells is not IL-4 dependent. J Immunol 1997; 159: 3731-3738.
22. Racke MK et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994; 180: 1961-1966.
23. Cash E et al. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 1994; 153: 4258-4267.
24. Kuchroo VK et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
25. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-386.
26. + Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest 1995; 95: 2979-2985.
27. Khoruts A, Miller SD, Jenkins MK. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 1995; 155: 5011-5017.
28. Ando DG et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989; 124: 132-143.
29. Katz JD, Benoist C, Mathis D. T helper subsets in insulin dependent diabetes. Science 1995; 268: 1185-1188.
30. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-38.
31. Saoudi A et al. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol 1993; 23: 3096-3103.
32. Rapoport MJ et al. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in non-obese diabetic mice. J Exp Med 1993; 178: 87-99.
33. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24: 1434-1440.
34. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993; 14: 335-337.
35. Wildbaum G, Youssef S, Grabie N, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies to interferon gamma inducing factor. J Immunol 1998; 161: 6368-6374.
36. Liu J et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med 1998; 4: 78-83.
37. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991; 34: 159-164.
38. Powell MB et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990; 2: 539-544.
39. Ruddle NH et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-1200.
40. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30: 694-700.
41. Thornhill MH et al. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592-598.
42. Korner H et al. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 1997; 27: 1973-1981.
43. Korner H et al. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186: 1585-1590.
44. Sean Riminton D et al. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient mice. J Exp Med 1998; 187: 1517-1528.
45. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 1997; 186: 1233-1240.
46. Taupin V et al. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol 1997; 27: 905-913.
47. Brenner T et al. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 1997; 158: 2940-2946.
48. Frei K et al. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 2177-2182.
49. Pan W et al. Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha. Am J Physiol 1996; 271: E636-E642.
50. Becher B, Dodelet V, Fedorowicz V, Antel JP. Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest 1996; 98: 1539-1543.
51. Selmaj K, Papierz W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995; 56: 135-141.
52. Riethmuller G et al. From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 1992; 129: 81-104.
53. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129-135.
54. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-245.
55. Ulmer JB, Sadoff JC, Liu MA. DNA vaccines. Curr Opin Immunol 1996; 8: 531-536.
56. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995; 377: 632-635.
57. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91: 9866-9870.
58. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-154.
59. Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein (see comments). Science 1993; 259: 1745-1749.
60. Sato Y et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-357.
61. Singh RR et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 1995; 181: 2017-2027.
62. Waisman A et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature Med 1996; 2: 899-905.
63. Youssef S et al. Long lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-3879.
64. Vandenbark AA et al. Specificity of T lymphocyte lines for peptides of myelin basic protein. J Immunol 1985; 135: 229-233.
65. Offner H et al. T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats. J Exp Med 1989; 170: 355-367.
66. Offner H et al. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. I. T cell receptor peptide regulation of T cell clones expressing cross-reactive V beta genes. J Immunol 1992; 148: 1706-1711.
67. Pette M et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770-1776.
68. Chen Y et al. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240.
69. Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994; 91: 6688-6692.
70. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176: 1355-1364.
71. Racke MK, Dhib JS, Cannella B et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991; 146: 3012-3017.
72. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187: 537-546.
73. Steinman L. Escape from 'horror autotoxicus': pathogenesis and treatment of autoimmune disease. Cell 1995; 80: 7-10.
74. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
75. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13: 11-16.
76. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire (see comments). Nature 1994; 371: 389-395.
77. Boyer JD et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination (see comments). Nature Med 1997; 3: 526-532.
78. Kim JJ et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
79. Kim JJ et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15: 641-646.
80. Raz E et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 1993; 90: 4523-4527.
81. Raz E et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 5141-5145.
82. Tascon RE et al. Vaccination against tuberculosis by DNA injection. Nature Med 1996; 2: 888-892.
83. Song XY, Gu M, Jin WW, Klinman DM, Wahl SM. Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101: 2615-2621.
84. Racke MK et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991; 146: 3012-3017.
85. Johns LD, Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J Neuroimmunol 1993; 47: 1-7.
86. Wahl SM et al. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 1993; 177: 225-230.
87. Giladi E et al. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol 1995; 7: 341-347.
88. Raz E et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
89. Fu TM et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3: 362-371.
90. Ramsdell F, Fowlkes BJ. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 1990; 248: 1342-1348.
91. Kappler J, Roehm N, Marrack P. T cell tolerance by clonal elemination in the thymus. Cell 1987; 49: 273-280.
92. Melamed D, Benschop RJ, Cambier JC, Nemazee D. Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. Cell 1998; 92: 173-182.
93. Critchfield JM et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-1143.
94. Critchfield JM, Lenardo MJ. Antigen-induced programmed T cell death as a new approach to immune therapy (review). Clin Immunol Immunopathol 1995; 75: 13-19.
95. Lider O et al. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomylitis. Science 1988; 239: 181-183.
96. Green LL et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7: 13-21.
97. Wallach D. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol 1984; 132: 2464-2469.